Product Name :
Br-PEG6-C2-acid
Description:
Br-PEG6-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
CAS:
309916-91-4
Molecular Weight:
417.29
Formula:
C15H29BrO8
Chemical Name:
1-bromo-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid
Smiles :
OC(=O)CCOCCOCCOCCOCCOCCOCCBr
InChiKey:
YKYMNNOFNSOFAR-UHFFFAOYSA-N
InChi :
InChI=1S/C15H29BrO8/c16-2-4-20-6-8-22-10-12-24-14-13-23-11-9-21-7-5-19-3-1-15(17)18/h1-14H2,(H,17,18)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Br-PEG6-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.HATU manufacturer |Product information|CAS Number: 309916-91-4|Molecular Weight: 417.Etokimab Protocol 29|Formula: C15H29BrO8|Chemical Name: 1-bromo-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid|Smiles: OC(=O)CCOCCOCCOCCOCCOCCOCCBr|InChiKey: YKYMNNOFNSOFAR-UHFFFAOYSA-N|InChi: InChI=1S/C15H29BrO8/c16-2-4-20-6-8-22-10-12-24-14-13-23-11-9-21-7-5-19-3-1-15(17)18/h1-14H2,(H,17,18)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:32067514 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|References:|An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562Products are for research use only. Not for human use.|